N-(4-(tert-butyl)benzyl)hydroxylamine | 681810-03-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-(tert-butyl)benzyl)hydroxylamine
• 英文别名: N-[(4-tert-butylphenyl)methyl]hydroxylamine；N-[4-tert-butylbenzyl]hydroxylamine
• CAS: 681810-03-7
• 化学式: C₁₁H₁₇NO
• 分子量: 179.262
• InChiKey: YGLOEZKLBWWTPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(4-(tert-butyl)benzyl)hydroxylamine 在 亚硝酸丁酯 、 氨 作用下， 以 乙醚 、 乙酸乙酯 为溶剂， 反应 0.67h， 生成
  参考文献：
  名称：

  Synthesis and tyrosinase inhibitory activity of novel N-hydroxybenzyl-N-nitrosohydroxylamines

  摘要：

  Several novel N-substituted N-nitrosohydroxylamines were synthesized. They all inhibited mushroom tyrosinase, but the type of inhibition was different depending on the substituent. Some N-(mono- or dihydroxybenzyl)-N-nitrosohydroxylamines exhibited uncompetitive inhibition with respect to (L)-dopa. Among them, compound 6 was also a competitive inhibitor with respect to oxygen. This observation suggests that another interaction by the meta- or para-hydroxyl group might stabilize the binding of the inhibitor to the enzyme through the oxygen binding site. (C) 2003 Elsevier Science (USA). All rights reserved.

  DOI：

  10.1016/s0045-2068(03)00026-9
• 作为产物：
  描述：

  4-叔丁基苄溴 在 sodium hydride 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N-(4-(tert-butyl)benzyl)hydroxylamine
  参考文献：
  名称：

  Analysis of structure–activity relationships for the ‘B-region’ of N-(4-t-butylbenzyl)-N′-[4-(methylsulfonylamino)benzyl]-thiourea analogues as TRPV1 antagonists

  摘要：

  The structure-activity relationships for the 'B-region' of N-(4-t-butylbenzyl)-N '-[4-(methylsulfonylamino)benzyl]thiourea analogues have been investigated as TRPV1 receptor antagonists. A docking model of potent antagonist 2 with the sensor region of TRPV1 is proposed. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.06.006

文献信息

• [EN] NOVEL N-HYDROXY THIOUREA, UREA AND AMIDE COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME<br/>[FR] NOUVEAUX COMPOSES DE N-HYDROXYTHIOUREE, D'UREE ET AMIDES ET LES COMPOSITIONS PHARMACEUTIQUES LES RENFERMANT
  申请人：DIGITAL BIOTECH CO LTD

  公开号：WO2004035533A1

  公开（公告）日：2004-04-29

  The present invention relates to novel n-hydroxythiourea, urea and amide compounds as a potent vanilloid receptor antagonist and the pharmaceutical compositions comprising the same. The inventive compound can be useful for analgesics to prevent, alleviate or treat pain diseases or inflammatory disease comprising pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease and urgent urinary incontinence.

  本发明涉及新型n-羟基硫脲、尿素和酰胺化合物，作为有效的辣椒素受体拮抗剂，以及包含这些化合物的药物组合物。这种创新化合物可用于镇痛药，用于预防、缓解或治疗疼痛疾病或包括疼痛的炎症性疾病，如急性疼痛、慢性疼痛、神经痛、术后疼痛、偏头痛、关节痛、神经病、神经损伤、糖尿病性神经病、神经退行性疾病、神经性皮肤疾病、中风、尿道膀胱过敏、肠易激综合征、哮喘或慢性阻塞性肺疾病等呼吸道疾病、皮肤、眼睛或粘膜刺激、发热、胃十二指肠溃疡、炎症性肠病、炎症性疾病和急性尿失禁。
• Novel n-hydroxy thiourea, urea and amide compounds and the pharmaceutical compositions comprising the same
  申请人：Lee Jee-Woo

  公开号：US20050288369A1

  公开（公告）日：2005-12-29

  The present invention relates to novel n-hydroxythiourea, urea and amide compounds as a potent vanilloid receptor antagonist and the pharmaceutical compositions comprising the same. The inventive compound can be useful for analgesics to prevent, alleviate or treat pain diseases or inflammatory disease comprising pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease and urgent urinary incontinence.

  本发明涉及新型的N-羟基硫脲、尿素和酰胺化合物，作为有效的vanilloid受体拮抗剂及其药物组合物。该创新化合物可用作镇痛药，用于预防、缓解或治疗疼痛疾病或伴随疼痛的炎症性疾病，包括急性疼痛、慢性疼痛、神经病性疼痛、术后疼痛、偏头痛、关节痛、神经病、神经损伤、糖尿病神经病变、神经退行性疾病、神经性皮肤病、中风、膀胱过敏、肠易激综合征、哮喘或慢性阻塞性肺疾病、皮肤、眼睛或黏膜刺激、发热、胃十二指肠溃疡、炎症性肠病、炎症性疾病和紧急尿失禁。
• Synthesis of Phosphinic Amides from Chlorophosphines and Hydroxyl Amines via P(III) to P(V) Rearrangement
  作者：Fang Cheng、Dongqiu Li、Jing Li、Yuhai Tang、Yong Wu、Silong Xu

  DOI：10.1021/acs.orglett.3c00229

  日期：——

  we devised a phosphorus-containing species as a radical precursor, but without the generation of phosphorus waste. Accordingly, a catalyst-free synthesis of phosphinic amides from hydroxyl amines and chlorophosphines via P(III) to P(V) rearrangement is described. Mechanistically, it may involve the initial formation of a R2N–O–PR2 species that undergoes homolysis of N–O bonds and subsequent radical

  膦酰基是产生新自由基的重要介质，但通常会产生化学计量的氧化膦/硫化物废物。在此，我们设计了一种含磷物质作为自由基前体，但不会产生磷废物。因此，描述了通过 P(III) 到 P(V) 重排从羟基胺和氯膦无催化剂合成次膦酰胺。从机理上讲，它可能涉及 R 2 N–O–PR 2物种的初始形成，该物种经历 N–O 键的均裂和随后的自由基重组。
• Evaluation of ketoclomazone and its analogues as inhibitors of 1-deoxy-<scp>d</scp>-xylulose 5-phosphate synthases and other thiamine diphosphate (ThDP)-dependent enzymes
  作者：Alex H. Y. Chan、Terence C. S. Ho、Imam Fathoni、Rawia Hamid、Anna K. H. Hirsch、Kevin J. Saliba、Finian J. Leeper

  DOI：10.1039/d4md00083h

  日期：——

  rely on the methylerythritol phosphate (MEP) pathway to obtain precursors of isoprenoids. 1-Deoxy-D-xylulose 5-phosphate synthase (DXPS), a thiamine diphosphate (ThDP)-dependent enzyme, catalyses the first and rate-limiting step of the MEP pathway. Due to its absence in humans, DXPS is considered as an attractive target for the development of anti-infectious agents and herbicides. Ketoclomazone is

  大多数病原菌、顶端复门寄生虫和植物依赖磷酸甲基赤藓糖醇 (MEP) 途径获取类异戊二烯前体。 1-脱氧-D-木酮糖 5-磷酸合酶 (DXPS) 是一种二磷酸硫胺素 (ThDP) 依赖性酶，催化 MEP 途径的第一步和限速步骤。由于人类中不存在 DXPS，DXPS 被认为是开发抗感染剂和除草剂的有吸引力的靶标。酮氯马酮是最早报道的 DXPS 抑制剂之一，其抗菌和除草活性已被记录。本研究调查了酮异恶草酮对不同物种的 DXPS 以及更广泛的 ThDP 依赖性酶家族的活性。为了进一步了解抑制作用，我们制备了酮异恶腙的类似物，并评估了它们在生化和计算研究中的活性。我们的研究结果支持酮异恶松作为选择性抗菌剂的潜力。
• NOVEL N-HYDROXY THIOUREA, UREA AND AMIDE COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：Digital Biotech Co., Ltd.

  公开号：EP1558574A1

  公开（公告）日：2005-08-03